Diagnosis and prognosis of acute respiratory distress syndrome related to diffuse pneumonic-type adenocarcinoma: a single-center case series study.

Intensive care unit (ICU) acute respiratory distress syndrome (ARDS) broncho-alveolar carcinoma lung cancer pneumonic-type adenocarcinoma (P-ADC)

Journal

Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 05 01 2022
accepted: 01 06 2022
entrez: 8 9 2022
pubmed: 9 9 2022
medline: 9 9 2022
Statut: ppublish

Résumé

The absence of diagnosis of acute respiratory distress syndrome (ARDS) concerns 20% of cancer patients and is associated with poorer outcomes. Diffuse pneumonic-type adenocarcinoma (P-ADC) is part of these difficult-to-diagnose ARDS, but only limited data are available regarding critically ill patients with diffuse P-ADC. We sought to describe the diagnosis process and the prognosis of P-ADC related ARDS patients admitted to the intensive care unit (ICU). Single-center observational case series study. All consecutive patients admitted to the ICU over a two-decade period presenting with (I) histologically or cytologically proven adenocarcinoma of the lung and (II) ARDS according to Berlin definition were included. Clinical, biological, radiological and cytological features of P-ADC were collected to identify diagnostic clues. Multivariate logistic regression analyses were performed to assess factors associated with ICU and hospital mortality. Among the 24 patients included [70 (61-75) years old, 17 (71%) males], the cancer diagnosis was performed during the ICU stay in 19 (79%), and 17 (71%) required mechanical ventilation. The time between the first symptoms and the diagnosis of P-ADC was 210 days (92-246 days). A non-resolving pneumonia after 2 (2 to 3) antibiotics lines observed in 23 (96%) patients with a 34 mg/L (19 to 75 mg/L) plasma C-reactive protein level at ICU admission. Progressive dyspnea, bronchorrhea, salty expectoration, fissural bulging and compressed bronchi and vessels were present in 100%, 83%, 69%, 57% and 43% of cases. Cytological examination of sputum or broncho-alveolar lavage provided a 75% diagnostic yield. The ICU and hospital mortality rates were 25% and 63%, respectively. The time (in days) between first symptoms and diagnosis [odds ratio (OR) 1.02, 95% confidence interval (95% CI): 1.00-1.03, P=0.046] and the Simplified Acute Physiology Score II (OR 1.16, 95% CI: 1.01-1.33, P=0.040) were independently associated with ICU mortality. Non-resolving pneumonia after several antibiotics lines without inflammatory syndrome, associated with progressive dyspnea, salty bronchorrhea, and lobar swelling (i.e., fissural bulging, compressed bronchi and vessels) were suggestive of P-ADC. Delayed diagnosis of diffuse P-ADC seemed an independent prognostic predictor and disease timely recognition may contribute to prognosis improvement.

Sections du résumé

Background UNASSIGNED
The absence of diagnosis of acute respiratory distress syndrome (ARDS) concerns 20% of cancer patients and is associated with poorer outcomes. Diffuse pneumonic-type adenocarcinoma (P-ADC) is part of these difficult-to-diagnose ARDS, but only limited data are available regarding critically ill patients with diffuse P-ADC. We sought to describe the diagnosis process and the prognosis of P-ADC related ARDS patients admitted to the intensive care unit (ICU).
Methods UNASSIGNED
Single-center observational case series study. All consecutive patients admitted to the ICU over a two-decade period presenting with (I) histologically or cytologically proven adenocarcinoma of the lung and (II) ARDS according to Berlin definition were included. Clinical, biological, radiological and cytological features of P-ADC were collected to identify diagnostic clues. Multivariate logistic regression analyses were performed to assess factors associated with ICU and hospital mortality.
Results UNASSIGNED
Among the 24 patients included [70 (61-75) years old, 17 (71%) males], the cancer diagnosis was performed during the ICU stay in 19 (79%), and 17 (71%) required mechanical ventilation. The time between the first symptoms and the diagnosis of P-ADC was 210 days (92-246 days). A non-resolving pneumonia after 2 (2 to 3) antibiotics lines observed in 23 (96%) patients with a 34 mg/L (19 to 75 mg/L) plasma C-reactive protein level at ICU admission. Progressive dyspnea, bronchorrhea, salty expectoration, fissural bulging and compressed bronchi and vessels were present in 100%, 83%, 69%, 57% and 43% of cases. Cytological examination of sputum or broncho-alveolar lavage provided a 75% diagnostic yield. The ICU and hospital mortality rates were 25% and 63%, respectively. The time (in days) between first symptoms and diagnosis [odds ratio (OR) 1.02, 95% confidence interval (95% CI): 1.00-1.03, P=0.046] and the Simplified Acute Physiology Score II (OR 1.16, 95% CI: 1.01-1.33, P=0.040) were independently associated with ICU mortality.
Conclusions UNASSIGNED
Non-resolving pneumonia after several antibiotics lines without inflammatory syndrome, associated with progressive dyspnea, salty bronchorrhea, and lobar swelling (i.e., fissural bulging, compressed bronchi and vessels) were suggestive of P-ADC. Delayed diagnosis of diffuse P-ADC seemed an independent prognostic predictor and disease timely recognition may contribute to prognosis improvement.

Identifiants

pubmed: 36071789
doi: 10.21037/jtd-22-12
pii: jtd-14-08-2812
pmc: PMC9442528
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2812-2825

Informations de copyright

2022 Journal of Thoracic Disease. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-12/coif). Maxens Decavèle reports non-financial support from ISIS medical. Michaël Duruisseaux declares grants, personal fees and non-financial support from Roche, Novartis, Pfizer, Takeda, Abbvie, BMS, MSD, ASTRAZENECA, Amgen, Boerhinger Ingelheim for participation to boards of experts, lectures, or congress. Marie Wislez reports grants from ASTRAZENECA, Lilly, Merck KgA, MERUS, GSK, AMGEN, Novartis, MSD, and personal fees from BMS, MSD, Boeringher, Roche, ASTRAZENECA and Novartis. The other authors have no conflicts of interest to declare.

Références

Am J Respir Crit Care Med. 2010 Oct 15;182(8):1038-46
pubmed: 20581167
Arch Intern Med. 1977 Jun;137(6):791-4
pubmed: 194543
Intensive Care Med. 2016 Feb;42(2):164-72
pubmed: 26408150
AJR Am J Roentgenol. 1998 Aug;171(2):359-63
pubmed: 9694451
Medicine (Baltimore). 2015 Feb;94(8):e540
pubmed: 25715252
Chest. 2017 Jan;151(1):193-203
pubmed: 27780786
J Clin Pathol. 1975 Jan;28(1):60-5
pubmed: 164485
Am J Hematol. 2005 Feb;78(2):94-9
pubmed: 15682425
Eur Respir J. 2003 Jan;21(1):187-91
pubmed: 12570127
Diagn Cytopathol. 1990;6(5):317-22
pubmed: 2292218
Br J Radiol. 2001 Jun;74(882):490-4
pubmed: 11459727
Ann Oncol. 2014 Sep;25(9):1829-1835
pubmed: 24950981
Chest. 2003 Jun;123(6):1868-77
pubmed: 12796162
Am J Clin Pathol. 1992 May;97(5):669-77
pubmed: 1575213
Pathologica. 2010 Dec;102(6):453-63
pubmed: 21428112
Crit Care Med. 2008 Jan;36(1):100-7
pubmed: 18090351
N Engl J Med. 2017 Aug 10;377(6):562-572
pubmed: 28792873
Br J Cancer. 2015 Mar 31;112 Suppl 1:S92-107
pubmed: 25734382
Ann Thorac Surg. 2002 Nov;74(5):1640-6; discussion 1646-7
pubmed: 12440623
Am J Respir Crit Care Med. 2008 Feb 15;177(4):433-9
pubmed: 17975197
Intensive Care Med. 2014 Aug;40(8):1106-14
pubmed: 24898895
Clin Cancer Res. 2021 Jul 15;27(14):4066-4076
pubmed: 33947695
Tumori. 2021 Jun;107(3):216-225
pubmed: 32762285
Cancer Discov. 2020 Jan;10(1):54-71
pubmed: 31658955
Am Rev Respir Dis. 1975 Jun;111(6):857-62
pubmed: 166581
Lancet Respir Med. 2019 Feb;7(2):173-186
pubmed: 30529232
Leuk Lymphoma. 2013 Aug;54(8):1724-9
pubmed: 23185988
Am J Clin Pathol. 2004 Jul;122(1):44-50
pubmed: 15272529
Chest. 2012 Feb;141(2):513-514
pubmed: 22315118
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Oncology. 1981;38(5):269-73
pubmed: 7022296
Chest. 2012 Nov;142(5):1338-1342
pubmed: 23131943
Acta Cytol. 2004 Jul-Aug;48(4):497-504
pubmed: 15296340
Medicine (Baltimore). 2019 May;98(18):e15420
pubmed: 31045800
Crit Care. 2006 Feb;10(1):R2
pubmed: 16356206
Ann Intensive Care. 2016 Dec;6(1):102
pubmed: 27783381
Proc Am Thorac Soc. 2011 Sep;8(5):381-5
pubmed: 21926387
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Intensive Care Med. 2009 Dec;35(12):2044-50
pubmed: 19768453

Auteurs

Maxens Decavèle (M)

Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Médecine Intensive Réanimation, Paris, France.
Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France.
Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Service de Médecine Intensive et Réanimation (R3S), Paris, France.

Antoine Parrot (A)

Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Pneumologie et Oncologie Thoracique and GRC-04 Theranoscan Sorbonne Université, Paris, France.

Michaël Duruisseaux (M)

Department of Respiratory Medicine, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, France.
Cancer Research Center of Lyon, Inserm 1052, CNRS 5286, Oncopharmacology Team, Lyon, France.

Martine Antoine (M)

Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Département d'Anatomie et cytologie pathologiques, Plateforme d'oncologie, Pathologie et biologie moléculaire, Paris, France.

Anne Fajac (A)

Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Département d'Anatomie et cytologie pathologiques, Plateforme d'oncologie, Pathologie et biologie moléculaire, Paris, France.

Audrey Milon (A)

Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon Service de Radiologie, Hôpital Tenon, Paris, France.

Marie-France Carette (MF)

Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon Service de Radiologie, Hôpital Tenon, Paris, France.

Anthony Canellas (A)

Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Pneumologie et Oncologie Thoracique and GRC-04 Theranoscan Sorbonne Université, Paris, France.

Aude Gibelin (A)

Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Médecine Intensive Réanimation, Paris, France.

Alexandre Elabbadi (A)

Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Médecine Intensive Réanimation, Paris, France.

Marie Wislez (M)

Université de Paris, Centre de Recherche des Cordeliers, Sorbonne Université, INSERM, Team Inflammation, Complement, and Cancer, Paris, France.
Oncology Thoracic Unit Pulmonology Department, AP-HP, Hôpital Cochin, Paris, France.

Jacques Cadranel (J)

Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Pneumologie et Oncologie Thoracique and GRC-04 Theranoscan Sorbonne Université, Paris, France.

Muriel Fartoukh (M)

Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Médecine Intensive Réanimation, Paris, France.

Classifications MeSH